Publications

CRISPR screens in the context of immune selection identify CHD1 and MAP3K7 as mediators of cancer immunotherapy resistance.

Authors: A Watterson, G Picco, V Veninga, Y Samarakoon, CM Cattaneo, SF Vieira, E Ka...

Research group: Halim Group

E-pub date: 20 Jan 2026

Journal name: Cell Rep Med

What if Every Patient’s Immune System Could be Guided by the World’s Most Powerful Computers to Fight Cancer? The UK Cancer Vaccines AI and Supercompute Project

Authors: ME Bryan, J Conway, G Bloomfield, A Matsunaga, D Narganes-Carlon, I Lowenho...

Research group: Mair Group

E-pub date: 20 Jan 2026

Journal name: EMJ Innovation

Developing Predictive and Robust Radiomics Models for Chemotherapy Response in High-Grade Serous Ovarian Carcinoma

Authors: S Hatamikia, G George, F Schwarzhans, A Mahbod, MA Reinius, AA Ardakani, M ...

Research group: Brenton Group

E-pub date: 13 Jan 2026

Journal name:

Lung Metastases in Pancreatic Cancer: Timing Their First Breath.

Authors: G Mucciolo, G Biffi

Research group: Biffi Group

E-pub date: 2 Jan 2026

Journal name: Cancer Res

Decay of driver mutations shapes the landscape of intestinal transformation.

Authors: FC Lourenço, ID Sadien, K Wong, S Adler, A Sawle, LS Santana, L Hazelwood,...

Research group: , Bioinformatics

E-pub date: 1 Jan 2026

Journal name: Nature

A toolkit for generating virtual brightfield images of histological and immunohistochemical stains from multiplexed data with AI-based channel selection and image enhancement.

Authors: T Whitmarsh, M Al Sa'd, E González Solares, A Molaeinezhad, MO Irfan, C Mu...

Research group: Hannon Group

E-pub date: 1 Jan 2026

Journal name: Front Bioinform

Symptom-triggered testing detects early stage and low volume resectable advanced stage ovarian cancer.

Authors: FLA Kwong, C Kristunas, C Davenport, J Deeks, S Mallett, R Agarwal, S Kehoe...

Research group: Brenton Group

E-pub date: 1 Jan 2026

Journal name: Int J Gynecol Cancer

Evaluating progesterone receptor agonist megestrol plus letrozole for women with early-stage estrogen-receptor-positive breast cancer: the window-of-opportunity, randomized, phase 2b, PIONEER trial.

Authors: RA Burrell, S Kumar, E Provenzano, C Pike, A Dayimu, SA McIntosh, V Pitsini...

Research group: Carroll Group

E-pub date: 1 Jan 2026

Journal name: Nat Cancer

Filters

Research Groups

Core Facilities

Start date

End date

CRISPR screens in the context of immune selection identify CHD1 and MAP3K7 as mediators of cancer immunotherapy resistance.

What if Every Patient’s Immune System Could be Guided by the World’s Most Powerful Computers to Fight Cancer? The UK Cancer Vaccines AI and Supercompute Project

Developing Predictive and Robust Radiomics Models for Chemotherapy Response in High-Grade Serous Ovarian Carcinoma

Lung Metastases in Pancreatic Cancer: Timing Their First Breath.

Decay of driver mutations shapes the landscape of intestinal transformation.

A toolkit for generating virtual brightfield images of histological and immunohistochemical stains from multiplexed data with AI-based channel selection and image enhancement.

Symptom-triggered testing detects early stage and low volume resectable advanced stage ovarian cancer.

Evaluating progesterone receptor agonist megestrol plus letrozole for women with early-stage estrogen-receptor-positive breast cancer: the window-of-opportunity, randomized, phase 2b, PIONEER trial.

Themes

Filters

Research Groups

Core Facilities

Start date

End date

CRISPR screens in the context of immune selection identify CHD1 and MAP3K7 as mediators of cancer immunotherapy resistance.

What if Every Patient’s Immune System Could be Guided by the World’s Most Powerful Computers to Fight Cancer? The UK Cancer Vaccines AI and Supercompute Project

Developing Predictive and Robust Radiomics Models for Chemotherapy Response in High-Grade Serous Ovarian Carcinoma

Lung Metastases in Pancreatic Cancer: Timing Their First Breath.

Decay of driver mutations shapes the landscape of intestinal transformation.

A toolkit for generating virtual brightfield images of histological and immunohistochemical stains from multiplexed data with AI-based channel selection and image enhancement.

Symptom-triggered testing detects early stage and low volume resectable advanced stage ovarian cancer.

Evaluating progesterone receptor agonist megestrol plus letrozole for women with early-stage estrogen-receptor-positive breast cancer: the window-of-opportunity, randomized, phase 2b, PIONEER trial.